Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Collegium Pharmaceutical Inc COLL

Healthcare
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed... see more

Recent & Breaking News (NDAQ:COLL)

Collegium Reports Record Quarterly Revenue of $87.7 Million

GlobeNewswire May 6, 2021

Collegium to Host Conference Call to Discuss First Quarter 2021 Financial Results and Provide Corporate Update

GlobeNewswire April 15, 2021

Collegium Reports Record Full-Year 2020 Revenue of $310.0 Million

GlobeNewswire February 25, 2021

Collegium to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and Provide Corporate Update

GlobeNewswire February 11, 2021

Monolithic Power Systems Set to Join S&P 500; Iridium Communications to Join S&P MidCap 400; Collegium Pharmaceutical to Join S&P SmallCap 600

PR Newswire February 8, 2021

Collegium Provides 2021 Financial Guidance

GlobeNewswire January 6, 2021

Collegium Reports Net Income of $11.3 Million in the Third Quarter of 2020

GlobeNewswire November 5, 2020

Collegium Announces Publication of "Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza® ER" in Pain Medicine

GlobeNewswire October 26, 2020

Collegium to Host Conference Call to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update

GlobeNewswire October 22, 2020

Collegium Announces Settlement with Teva Resolving Xtampza® ER Patent Litigation

GlobeNewswire September 30, 2020

Collegium Appoints Rita Balice-Gordon to its Board of Directors

GlobeNewswire September 25, 2020

Collegium Announces Five Posters Presented at PAINWeek 2020 National Conference

GlobeNewswire September 14, 2020

Collegium Announces Scientific Presentations at PAINWeek 2020 National Conference

GlobeNewswire September 9, 2020

Collegium Reports Net Income of $8.1 Million in the Second Quarter of 2020

GlobeNewswire August 5, 2020

Collegium to Host Conference Call to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update

GlobeNewswire July 21, 2020

Collegium Pharmaceutical Named one of Boston Business Journal's 2020 Best Places to Work

GlobeNewswire June 17, 2020

Collegium Reports First Quarter 2020 Profitability

GlobeNewswire May 7, 2020

Collegium to Host Conference Call to Discuss First Quarter 2020 Financial Results and Provide Corporate Update

GlobeNewswire April 23, 2020

Collegium to Participate in Upcoming Investor Conference

GlobeNewswire April 7, 2020

Collegium Reports Full-Year 2019 Revenue of $296.7 Million

GlobeNewswire February 27, 2020